Skip to main content

Table 1 VEGFR-3 expression in lymphatics of normal mammary gland, benign and malignant tumours.

From: Lymphatic vessels assessment in feline mammary tumours

Groups

N° of lymphatics

Spearman test

 

without VEGFR-3 (mean ± st. err; median)

with VEGFR-3 (mean ± st. err; median)

 

Normal mammary gland

  

avsb **

intramammary

2.43 ± 0.54; 2.16a

0.79 ± 0.18; 1.03c

cvsd **

extramammary

4.03 ± 0.53; 4.55b

2.75 ± 0.41; 2.66d

evsf NS

Benign tumours

  

gvsh **

intratumoral

2.80 ± 0.66; 2.33e

0.93 ± 0.21; 1.05g

ivsl **

extratumoral

4.20 ± 0.49; 3.76f

2.64 ± 0.36; 2.53h

mvsn **

Malignant tumours

  

avsevsi NS

intratumoral

3.76 ± 0.27; 3.50i

1.30 ± 0.18; 1.10m

bvsfvsl *

extratumoral

4.55 ± 0.22; 4.44l

3.03 ± 0.15; 3.01n

cvsgvsm NS

dvshvsn NS

Malignant tumours intratumoral

   

Stage 0

3.25 ± 0.44; 3.15o

0.73 ± 0.25; 0.70r

 

Stage I

4.07 ± 0.47; 3.70p

1.43 ± 0.42; 0.80s

ovspvsq NS

Stage II

5.06 ± 0.51; 4.58q

3.20 ± 0.34; 3.35t

rvssvst *

Malignant tumours extratumoral

  

uvsvvsw NS

Stage 0

3.52 ± 0.32; 3.37u

2.52 ± 0.25; 2.35x

xvsyvsz NS

Stage I

5.06 ± 0.51; 4.58v

3.20 ± 0.34; 3.35y

 

Stage II

4.59 ± 0.17; 4.52w

3.12 ± 0.18; 3.15z

 
  1. Descriptive statistical data of the number of lymphatics with or without VEGFR-3 expression in the compared groups. Spearman test: * = P < 0.05; ** = P < 0.01; NS = non-significant.